BPC-157 in the laboratory: tendon, gut and blood vessels

Key points

• In rats with a transected Achilles tendon, BPC-157 was associated with higher load to failure, a better functional index and more fibroblast, reticulin and collagen formation than controls [2].
• An independent group in Taiwan described greater migration and survival under oxidative stress in tendon fibroblasts, with FAK and paxillin activation, and no direct effect on proliferation [6].
• In the rat gut, closure of external and internal fistulas and better anastomotic healing have been described, even with the peptide given in drinking water [1][8][9].
• In endothelium, BPC-157 was associated with VEGFR2 up-regulation and activation, the Akt-eNOS pathway and nitric-oxide-dependent vasodilation [10][11].
• No phase 2 trial has been completed. Human evidence is limited to fewer than 30 people in uncontrolled series [13].

US status (October 2026): Not FDA-approved, with no lawful compounding pathway as of September 25, 2026. MDside providers do not prescribe it. BPC-157 status page.

The animal data are consistent. The human data are missing.

BPC-157 is a pentadecapeptide (GEPPPGKPADDAGLV, molecular weight 1419) [2] that corresponds to a partial sequence of body protection compound, a protein isolated from human gastric juice [6]. Its most cited chemical feature is stability: the Zagreb group describes it as stable in human gastric juice for more than 24 hours [9], which is unusual for a peptide and explains why it was studied orally from the start.

Patients who ask you about BPC-157 have usually heard about the 2026 regulatory story. That is covered in BPC-157: from the Rogan podcast to the FDA vote. This article covers what happens in the laboratory, so you can answer the clinical question on its merits.

• More than 24 h: stability described in human gastric juice [9]
• 35 of 36: musculoskeletal studies in a systematic review were preclinical [14]
• Under 30 min: plasma half-life in rats and dogs [12]

Tendon, ligament and muscle respond the same way in rats

The reference study is Staresinic and colleagues (2003). In rats with a transected Achilles tendon, daily intraperitoneal BPC-157 was associated, versus saline, with higher load to failure and Young’s modulus, higher Achilles functional index values, more fibroblasts, reticulin and collagen, and a smaller tendon defect, assessed between days 1 and 14 [2]. In culture, the peptide did not stimulate tenocyte growth on its own. It reversed the inhibition caused by 4-hydroxynonenal, a lipid-peroxidation aldehyde [2].

The same pattern appears in other structures. In Achilles detachment from the calcaneus, an injury that does not heal spontaneously in the rat, BPC-157 was associated with better function, stiffness and load to failure, more type I collagen and better fiber organization up to day 21. It also reduced the healing impairment induced by methylprednisolone [3]. In the medial collateral ligament, followed for 90 days, it was associated with better functional, biomechanical and histological healing given intraperitoneally, topically as a cream and orally in drinking water [4]. In gastrocnemius crush injury there was less hematoma and edema, no contracture and lower creatine kinase and other enzymes [5].

An independent laboratory confirmed the cell mechanism

Much of the mechanistic explanation comes from Chang Gung University in Taiwan, a group unrelated to Zagreb. In rat Achilles tendon explants, BPC-157 accelerated fibroblast outgrowth. In the MTT assay it did not directly change proliferation. It increased cell survival under hydrogen peroxide stress and dose-dependently increased fibroblast migration and spreading, with more F-actin [6]. Phosphorylation of FAK and paxillin, two focal-adhesion proteins, rose with dose while their total amounts were unchanged [6]. The described effect is mobilizing and protecting the cells that repair tissue. It does not make tissue grow.

In a 2018 review, the Zagreb group compared BPC-157 with the classic angiogenic growth factors (EGF, FGF, VEGF). It argued that only BPC-157 was consistently effective in all models of acute and chronic gastrointestinal injury, given intraperitoneally, orally or locally, and that with the same regimens it improved tendon, ligament and bone healing [7]. That is the authors’ own thesis. It does capture what makes this literature distinctive: a single peptide, with no carrier, with one dose range shared across very different tissues.

The gut is the original territory

In rats, healing of gastrocutaneous, duodenocutaneous and colocutaneous fistulas has been described, with closure even when treatment began one month after the fistula was created. In a 4-week short-bowel model it was associated with weight gain and greater villus height and crypt depth [1]. A 2020 review extends the list to internal fistulas (colovesical, rectovaginal) and to esophagogastric, jejunoileal, colocolic and other anastomoses [9].

One example shows the link to nitric oxide. In rat esophagogastric anastomosis, a typically lethal model, BPC-157, injected or in drinking water, eliminated mortality over the 4 days of follow-up. The NO-synthase blocker L-NAME worsened the course, and BPC-157 cancelled that worsening [8]. The authors interpret the anastomosis as a “disability” of the nitric oxide system that the peptide corrects [8].

In vessels, the signal runs through VEGFR2 and nitric oxide

The Taiwanese group also studied the vascular component. BPC-157 increased vessel density in the chick chorioallantoic membrane and endothelial tube formation. In rats with hind-limb ischemia it accelerated blood-flow recovery measured by laser Doppler and increased vessel numbers [10]. In human endothelial cells it increased VEGFR2 expression, but not VEGF-A, promoted receptor internalization and activated the VEGFR2-Akt-eNOS pathway. The endocytosis inhibitor dynasore blocked these effects [10].

A second study described concentration-dependent vasodilation in isolated rat aorta, attenuated without endothelium and suppressed by L-NAME or hemoglobin, meaning it was mediated by nitric oxide. The proposed mechanism is activation of Src and caveolin-1, which releases eNOS from its binding to caveolin [11]. These findings give a coherent molecular basis to what Zagreb observed in tendon and gut: more perfusion and more endothelial signaling in injured tissue.

The pharmacokinetics do not match the effects

Oral efficacy in the ligament and anastomosis models [4][8] is consistent with the described gastric stability. It has not been characterized in humans. The only formal pharmacokinetic study, from an independent Chinese group, found in rats and dogs a half-life under 30 minutes, intramuscular bioavailability of 14 to 19% in rats and 45 to 51% in dogs, and rapid breakdown into small fragments and amino acids [12]. A 2026 pharmaceutical review calls this a pharmacokinetic-pharmacodynamic disconnect: a half-life of minutes against biological effects lasting hours to days [13].

“The primary barrier to clinical translation is not the absence of biological activity, but the absence of fundamental pharmaceutical science.” (Mateescu and colleagues, Pharmaceutics, 2026 [13])

Where the evidence ends

The limits are as concrete as the findings. A 2025 systematic review included 36 musculoskeletal studies: 35 preclinical and 1 clinical [14]. BPC-157 was tested as PL 14736 in trials for inflammatory bowel disease, described by the Zagreb group as safe [1]. The 2026 review notes that no phase 2 trial has been completed and that clinical data come from fewer than 30 people in three uncontrolled pilot studies without standardized pharmaceutical preparations [13]. Most of the animal literature comes from a single group in Zagreb. The Taiwanese and Chinese laboratories provide mechanistic and pharmacokinetic replication, not efficacy trials [6][10][12].

The pro-angiogenic effect also raises a theoretical question about tumor growth, covered in the article on the FDA and BPC-157. The Zagreb group replies that BPC-157 does not produce corneal neovascularization and instead opposes it, and describes anti-tumor potential in vivo and in vitro [15]. No human data can yet settle the question.

What this means for your practice. BPC-157’s strongest feature is consistency: tendon, ligament, muscle, mucosa and endothelium respond in animal models with a common pattern of cell migration, protection against stress and VEGFR2/eNOS signaling [2][6][10][11]. What is missing is what any drug is asked for: characterized formulations, human pharmacokinetics and controlled trials [13]. Products sold as BPC-157 today are labeled “research use only,” a framing we cover in research-use-only peptides. For where the compound stands with FDA, see the peptide status tracker.

References

1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PMID 21548867. Link
2. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. PMID 14554208. Link
3. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-9. PMID 16583442. Link
4. Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-61. PMID 20225319. Link
5. Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-25. PMID 18668315. Link
6. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PMID 21030672. Link
7. Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID 29998800. Link
8. Djakovic Z, et al. Esophagogastric anastomosis in rats: improved healing by BPC 157 and L-arginine, aggravated by L-NAME. World J Gastroenterol. 2016;22(41):9127-9140. PMID 27895400. Link
9. Sikiric P, et al. Fistulas healing. Stable gastric pentadecapeptide BPC 157 therapy. Curr Pharm Des. 2020;26(25):2991-3000. PMID 32329684. Link
10. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966. Link
11. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID 33051481. Link
12. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. Link
13. Mateescu DM, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625. PMID 42198317. Link
14. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949. Link
15. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 as a therapy and safety key: a special beneficial pleiotropic effect controlling and modulating angiogenesis and the NO-system. Pharmaceuticals (Basel). 2025;18(6):928. PMID 40573323. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.